Diametric Capital LP Takes $86,000 Position in PetMed Express, Inc. (NASDAQ:PETS)

Diametric Capital LP purchased a new position in shares of PetMed Express, Inc. (NASDAQ:PETS) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 17,894 shares of the company’s stock, valued at approximately $86,000.

Other institutional investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership lifted its position in PetMed Express by 26.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company’s stock worth $2,474,000 after buying an additional 107,614 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of PetMed Express by 355.5% in the fourth quarter. JPMorgan Chase & Co. now owns 106,954 shares of the company’s stock worth $516,000 after acquiring an additional 83,473 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of PetMed Express during the fourth quarter worth $58,000. Blair William & Co. IL boosted its position in PetMed Express by 95.2% during the fourth quarter. Blair William & Co. IL now owns 20,300 shares of the company’s stock valued at $98,000 after purchasing an additional 9,900 shares during the last quarter. Finally, R Squared Ltd purchased a new position in PetMed Express in the fourth quarter valued at about $31,000. 73.33% of the stock is currently owned by institutional investors and hedge funds.

PetMed Express Price Performance

PetMed Express stock opened at $4.00 on Thursday. PetMed Express, Inc. has a one year low of $2.90 and a one year high of $6.85. The company’s fifty day moving average price is $4.42 and its two-hundred day moving average price is $4.54. The company has a market capitalization of $82.62 million, a price-to-earnings ratio of 400.40 and a beta of 0.78.

PetMed Express (NASDAQ:PETS) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. As a group, sell-side analysts anticipate that PetMed Express, Inc. will post 0.19 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered PetMed Express from a “buy” rating to a “hold” rating in a report on Tuesday, February 11th.

PetMed Express Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.